BIMI Holdings Inc (OQ:BIMI)
Business Focus: N/A
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 725 5Th Avenue, 15Th Floor, 15-01 NEW YORK NY 404100 |
| Tel: | 1-949-9816274 |
| Website: | https://usbimi.com |
| IR: | See website |
| Key People | ||
| Fnu Oudom Chairman of the Board, President | Tiewei Song Chief Executive Officer, Director | Baiqun Zhong Interim Chief Financial Officer |
| Business Overview |
| BIMI Holdings Inc., formerly BIMI International Medical Inc., is a healthcare products and services provider. The Company offers a range of healthcare products and related services in the United States and Asia. The Company operates in four segments: wholesale pharmaceuticals, wholesale medical devices, medical services and retail pharmacy. The wholesale pharmaceuticals segment includes supplying prescription and over the counter (OTC) medicines, traditional Chinese medicines (TCM), healthcare supplies and sundry items to clinics, third party pharmacies, hospitals and other drug wholesalers. The wholesale medical devices segment distributes medical devices, including medical consumables, to private clinics, hospitals, third party pharmacies and other medical device dealers. The retail pharmacy segment sells prescription and OTC medicines, TCM, healthcare supplies and sundry items to retail customers through its directly owned pharmacies and authorized retail stores. |
| Financial Overview |
| For the nine months ended 30 September 2023, BIMI Holdings Inc revenues increased 8% to $11.3M. Net loss before extraordinary items decreased 92% to $1M. Revenues reflect Medical device wholesale segment increase from $576K to $1.2M, Retail pharmacy segment increase from $114K to $257K. Lower net loss reflects General and administrative decrease of 34% to $5.2M (expense), Non-operating expense decrease of 94% to $148K (expense). |
| Employees: | 296 as of Dec 31, 2022 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $15.52M as of Sep 30, 2023 |
| Annual revenue (TTM): | $12.63M as of Sep 30, 2023 |
| EBITDA (TTM): | -$3.54M as of Sep 30, 2023 |
| Net annual income (TTM): | -$10.52M as of Sep 30, 2023 |
| Free cash flow (TTM): | -$2.90M as of Sep 30, 2023 |
| Net Debt Last Fiscal Year: | $0.30M as of Sep 30, 2023 |
| Shares outstanding: | 13,589,569 as of Jan 2, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.